Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.

Monforte Ad, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA.

AIDS. 2013 Jan 28;27(3):407-15. doi: 10.1097/QAD.0b013e32835b2ef1.

PMID:
23291539
2.

High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.

Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

Clin Infect Dis. 2012 Nov;55(9):1262-9. doi: 10.1093/cid/cis621. Epub 2012 Jul 19.

3.

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?

Hamada Y, Nishijima T, Komatsu H, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2013 Jul 16;8(7):e69845. doi: 10.1371/journal.pone.0069845. Print 2013.

4.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team.

AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.

PMID:
20613461
5.

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.

Int J Clin Pract. 2011 Dec;65(12):1240-9. doi: 10.1111/j.1742-1241.2011.02807.x. Epub 2011 Oct 14.

PMID:
21999631
6.

Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.

Busti AJ, Bedimo R, Margolis DM, Hardin DS.

J Investig Med. 2008 Feb;56(2):539-44. doi: 10.231/JIM.0b013e3181641b26.

PMID:
18317438
7.

[Clinical utility of atazanavir].

Ribera Pascuet E, Curran A.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:55-67. doi: 10.1016/S0213-005X(08)76622-9. Review. Spanish.

PMID:
20116619
8.

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.

Nishijima T, Hamada Y, Watanabe K, Komatsu H, Kinai E, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2013 Oct 10;8(10):e77268. doi: 10.1371/journal.pone.0077268. eCollection 2013.

9.

Class of antiretroviral drugs and the risk of myocardial infarction.

DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD.

N Engl J Med. 2007 Apr 26;356(17):1723-35.

10.

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

Antivir Ther. 2006;11(1):53-62.

PMID:
16518960
11.

Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.

Macassa E, Delaugerre C, Teglas JP, Jullien V, Tréluyer JM, Veber F, Rouzioux C, Blanche S.

Pediatr Infect Dis J. 2006 Sep;25(9):809-14.

PMID:
16940839
12.

Atazanavir: in pediatric patients with HIV-1 infection.

Deeks ED.

Paediatr Drugs. 2012 Apr 1;14(2):131-41. doi: 10.2165/11208550-000000000-00000. Review.

PMID:
22292486
13.

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Arch Intern Med. 2010 Jul 26;170(14):1228-38. doi: 10.1001/archinternmed.2010.197.

PMID:
20660842
14.

Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.

Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH; SABAR Study Team.

AIDS. 2010 Mar 27;24(6):885-90. doi: 10.1097/QAD.0b013e3283352ed5.

PMID:
19952712
15.

Atazanavir/ritonavir: a review of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Review.

PMID:
18389089
16.

The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.

Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B.

AIDS. 2007 Jun 19;21(10):1309-15.

PMID:
17545707
17.

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D; 089 Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):161-7.

PMID:
17971713
18.

Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

HIV Med. 2010 May;11(5):326-33. doi: 10.1111/j.1468-1293.2009.00785.x. Epub 2010 Dec 9.

19.

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J.

J Infect Dis. 2010 Feb 1;201(3):318-30. doi: 10.1086/649897.

20.
Items per page

Supplemental Content

Write to the Help Desk